EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited

View source ↗

Summary

Authorised status for Kesimpta (ofatumumab) in relapsing-remitting multiple sclerosis in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Novartis Europharm Limited. Decision date: 09/07/2026